UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 3, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $.05 par valuePFENew York Stock Exchange

0.250% Notes due 2022PFE22New York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At November 8, 2021, 5,612,866,598 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

10

Notes to Condensed Consolidated Financial Statements

11

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

39

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

62

Item 4.

Controls and Procedures

62

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

62

Item 1A.

Risk Factors

62

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

62

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other InformationN/A

Item 6.

Exhibits

63

Signature

63

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 29, 2021 and August 23, 2020, and for U.S. subsidiaries is as of and for the three and nine months ended October 3, 2021 and September 27, 2020. References to Notes in this Form 10-Q are to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined:

2020 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2020

ACIPAdvisory Committee on Immunization Practices

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AllogeneAllogene Therapeutics, Inc.

ArrayArray BioPharma Inc.

ArvinasArvinas, Inc.

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BioNTechBioNTech SE

BLABiologics License Application

BMSBristol-Myers Squibb Company

BNT162b2Pfizer BioNTech COVID-19 Vaccine

ComirnatyPfizer-BioNTech COVID-19 Vaccine

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

CMAconditional marketing authorization

Consumer Healthcare JVGSK Consumer Healthcare JV

COVID-19novel coronavirus disease of 2019

Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and Finland

Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Canada, South Korea, Australia and New Zealand

Developed Rest of WorldIncludes the following markets: Japan, Canada, South Korea, Australia and New Zealand

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey

EPSearnings per share

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FDAU.S. Food and Drug Administration

Form 10-QQuarterly Report on Form 10-Q for the quarterly period ended October 3, 2021

GAAPGenerally Accepted Accounting Principles

GISTgastrointestinal stromal tumors

GSKGlaxoSmithKline plc

HospiraHospira, Inc.

IPR&Din-process research and development

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LIBORLondon Interbank Offered Rate

LillyEli Lilly & Company

LOEloss of exclusivity

MCOmanaged care organization

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MeridianMeridian Medical Technologies, Inc.

MTMmark-to-market

MylanMylan N.V.

Mylan-Japan collaborationa pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020

MyovantMyovant Sciences Ltd.

nmCRPCnon-metastatic castration-resistant prostate cancer

NSCLCnon-small cell lung cancer

OPKOOPKO Health, Inc.

OTCover-the-counter

PaxlovidPF-07321332 (SARS-CoV-2 3CL protease inhibitor (oral anti-viral)); ritonavir

PBMpharmacy benefit manager

PDUFAPrescription Drug User Fee Act

PGSPfizer Global Supply

PharmaciaPharmacia Corporation

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

RCCrenal cell carcinoma

R&Dresearch and development

SandozSandoz, Inc., a division of Novartis AG

SECU.S. Securities and Exchange Commission

SI&Aselling, informational and administrative

UCulcerative colitis

U.K.United Kingdom

U.S.United States

Upjohn BusinessPfizer s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris

ValnevaValneva SE

ViatrisViatris Inc.

YTDYear-to-date or nine months ended

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months EndedNine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Revenues$24,094 $10,277 $57,653 $30,224

Costs and expenses:

Cost of sales(a)

9,973 2,007 21,232 5,773

Selling, informational and administrative expenses(a)

2,905 2,658 8,617 7,858

Research and development expenses(a)

3,447 2,300 7,920 6,050

Amortization of intangible assets981 862 2,784 2,579

Restructuring charges and certain acquisition-related costs

646 2 668 417

(Gain) on completion of Consumer Healthcare JV transaction

(6)

Other (income)/deductions net

(1,696)1,878 (3,697)1,114

Income from continuing operations before provision/(benefit) for taxes on income7,836 570 20,128 6,438

Provision/(benefit) for taxes on income(331)(347)1,518 434

Income from continuing operations8,167 917 18,610 6,004

Income/(loss) from discontinued operations net of tax(9)560 24 2,334

Net income before allocation to noncontrolling interests8,159 1,477 18,633 8,338

Less: Net income attributable to noncontrolling interests12 8 47 25

Net income attributable to Pfizer Inc. common shareholders$8,146 $1,469 $18,586 $8,313

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$1.45 $0.16 $3.32 $1.08

Income/(loss) from discontinued operations net of tax 0.10 0.42

Net income attributable to Pfizer Inc. common shareholders$1.45 $0.26 $3.32 $1.50

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$1.42 $0.16 $3.26 $1.06

Income/(loss) from discontinued operations net of tax 0.10 0.42

Net income attributable to Pfizer Inc. common shareholders$1.42 $0.26 $3.27 $1.48

Weighted-average shares basic5,609 5,557 5,597 5,552

Weighted-average shares diluted5,725 5,633 5,688 5,622

(a)Exclusive of amortization of intangible assets, except as disclosed in Note 9 in this Form 10-Q and Note 1L in our 2020 Form 10-K.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months EndedNine Months Ended

(MILLIONS)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Net income before allocation to noncontrolling interests$8,159 $1,477 $18,633 $8,338

Foreign currency translation adjustments, net(866)1,403 (366)(27)

Unrealized holding gains/(losses) on derivative financial instruments, net213 (372)179 (661)

Reclassification adjustments for (gains)/losses included in net income(a)

48 143 286 (25)

261 (230)464 (685)

Unrealized holding gains/(losses) on available-for-sale securities, net(266)239 (128)231

Reclassification adjustments for (gains)/losses included in net income(b)

9 (85)(172)(25)

(257)155 (300)205

Reclassification adjustments related to amortization of prior service costs and other, net(39)(45)(119)(134)

Reclassification adjustments related to curtailments of prior service costs and other, net(59) (59)

Other2 (3)(3)1

(97)(47)(181)(133)

Other comprehensive income/(loss), before tax(959)1,280 (382)(640)

Tax provision/(benefit) on other comprehensive income/(loss)(65)(19)(44)(311)

Other comprehensive income/(loss) before allocation to noncontrolling interests$(894)$1,299 $(338)$(329)

Comprehensive income/(loss) before allocation to noncontrolling interests$7,265 $2,776 $18,296 $8,009

Less: Comprehensive income/(loss) attributable to noncontrolling interests9 11 48 16

Comprehensive income/(loss) attributable to Pfizer Inc.$7,256 $2,766 $18,248 $7,993

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)October 3,

2021December 31, 2020

(Unaudited)

Assets

Cash and cash equivalents$1,966 $1,784

Short-term investments27,730 10,437

Trade accounts receivable, less allowance for doubtful accounts: 2021 $494; 2020 $508

11,897 7,930

Inventories8,640 8,046

Current tax assets3,877 3,264

Other current assets3,790 3,605

Total current assets57,900 35,067

Equity-method investments16,349 16,856

Long-term investments5,248 3,406

Property, plant and equipment, less accumulated depreciation: 2021 $15,403; 2020 $14,812

14,436 13,900

Identifiable intangible assets26,306 28,471

Goodwill49,489 49,577

Noncurrent deferred tax assets and other noncurrent tax assets2,755 2,383

Other noncurrent assets6,705 4,569

Total assets$179,188 $154,229

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2021 $2,663; 2020 $2,002

$3,629 $2,703

Trade accounts payable4,698 4,309

Dividends payable2,191 2,162

Income taxes payable4,496 1,049

Accrued compensation and related items2,571 3,058

Deferred revenues3,529 1,113

Other current liabilities20,690 11,527

Total current liabilities41,803 25,920

Long-term debt36,250 37,133

Pension benefit obligations3,676 4,766

Postretirement benefit obligations627 645

Noncurrent deferred tax liabilities328 4,063

Other taxes payable11,336 11,560

Other noncurrent liabilities9,201 6,669

Total liabilities103,221 90,756

Commitments and Contingencies

Common stock473 470

Additional paid-in capital89,973 88,674

Treasury stock(111,359)(110,988)

Retained earnings102,252 90,392

Accumulated other comprehensive loss(5,649)(5,310)

Total Pfizer Inc. shareholders equity75,691 63,238

Equity attributable to noncontrolling interests275 235

Total equity75,967 63,473

Total liabilities and equity$179,188 $154,229

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, July 4, 2021

$ 9,450 $472 $89,336 (3,851)$(111,356)$96,346 $(4,758)$70,042 $273 $70,315

Net income8,146 8,146 12 8,159

Other comprehensive income/(loss), net of tax

(891)(891)(3)(894)

Cash dividends declared, per share: $0.39

Common stock(2,192)(2,192)(2,192)

Preferred stock

Noncontrolling interests (8)(8)

Share-based payment transactions13 1 637 (3)(1)634 634

Purchases of common stock

Preferred stock conversions and redemptions

Other (47)(47)1 (46)

Balance, October 3, 2021

$ 9,462 $473 $89,973 (3,851)$(111,359)$102,252 $(5,649)$75,691 $275 $75,967

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, June 28, 2020

$ 9,394 $470 $87,886 (3,840)$(110,978)$93,946 $(6,983)$64,342 $228 $64,570

Net income1,469 1,469 8 1,477

Other comprehensive income/(loss), net of tax1,296 1,296 3 1,299

Cash dividends declared, per share: $0.38

Common stock (2,113)(2,113)(2,113)

Preferred stock

Noncontrolling interests (1)(1)

Share-based payment transactions3 275 (2)273 273

Purchases of common stock

Preferred stock conversions and redemptions

Other (1)(1)

Balance, September 27, 2020

$ 9,397 $470 $88,161 (3,840)$(110,980)$93,302 $(5,687)$65,267 $236 $65,503

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 2021

$ 9,407 $470 $88,674 (3,840)$(110,988)$90,392 $(5,310)$63,238 $235 $63,473

Net income18,586 18,586 47 18,633

Other comprehensive income/(loss), net of tax(338)(338) (338)

Cash dividends declared, per share: $1.17

Common stock(6,569)(6,569)(6,569)

Preferred stock

Noncontrolling interests (8)(8)

Share-based payment transactions56 3 1,300 (11)(371)(77)855 855

Purchases of common stock

Preferred stock conversions and redemptions

Other (81)(81)1 (79)

Balance, October 3, 2021

$ 9,462 $473 $89,973 (3,851)$(111,359)$102,252 $(5,649)$75,691 $275 $75,967

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 2020

431 $17 9,369 $468 $87,428 (3,835)$(110,801)$91,397 $(5,367)$63,143 $303 $63,447

Net income8,313 8,313 25 8,338

Other comprehensive income/(loss), net of tax(319)(319)(9)(329)

Cash dividends declared, per share: $1.14

Common stock (6,408)(6,408)(6,408)

Preferred stock

Noncontrolling interests (81)(81)

Share-based payment transactions28 1 748 (6)(210)539 539

Purchases of common stock

Preferred stock conversions and redemptions(431)(17)(15)1 31 (1)(1)

Other (1)(1)

Balance, September 27, 2020

$ 9,397 $470 $88,161 (3,840)$(110,980)$93,302 $(5,687)$65,267 $236 $65,503

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS)October 3,

2021September 27,

2020

Operating Activities

Net income before allocation to noncontrolling interests$18,633 $8,338

Income from discontinued operations net of tax24 2,334

Net income from continuing operations before allocation to noncontrolling interests18,610 6,004

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization3,914 3,573

Asset write-offs and impairments115 989

Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed (6)

Deferred taxes from continuing operations(3,702)(735)

Share-based compensation expense687 468

Benefit plan contributions in excess of expense/income(1,933)(760)

Other adjustments, net(1,848)(313)

Other changes in assets and liabilities, net of acquisitions and divestitures10,816 (2,856)

Net cash provided by operating activities from continuing operations26,660 6,364

Net cash provided by operating activities from discontinued operations6 2,414

Net cash provided by operating activities26,666 8,778

Investing Activities

Purchases of property, plant and equipment(1,718)(1,413)

Purchases of short-term investments(26,280)(9,309)

Proceeds from redemptions/sales of short-term investments15,852 8,397

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(7,152)671

Purchases of long-term investments(861)(284)

Proceeds from redemptions/sales of long-term investments569 648

Other investing activities, net(370)160

Net cash provided by/(used in) investing activities from continuing operations(19,960)(1,129)

Net cash provided by/(used in) investing activities from discontinued operations (11,472)

Net cash provided by/(used in) investing activities(19,960)(12,601)

Financing Activities

Proceeds from short-term borrowings 12,352

Principal payments on short-term borrowings(1)(17,449)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

265 1,624

Proceeds from issuance of long-term debt997 5,222

Principal payments on long-term debt(1,001)(2,511)

Cash dividends paid(6,540)(6,328)

Other financing activities, net(185)(166)

Net cash provided by/(used in) financing activities from continuing operations(6,465)(7,257)

Net cash provided by/(used in) financing activities from discontinued operations 11,395

Net cash provided by/(used in) financing activities(6,465)4,138

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(32)(39)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents209 277

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,825 1,350

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$2,034 $1,627

Supplemental Cash Flow Information

Cash paid/(received) during the period for:

Income taxes

$2,943 $2,445

Interest paid

1,205 1,297

Interest rate hedges

(26)(45)

Non-cash transaction:

Right-of-use assets obtained in exchange for lease liabilities$1,552 $157

See Accompanying Notes.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in Note 1C. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 29, 2021 and August 23, 2020, and for U.S. subsidiaries is as of and for the three and nine months ended October 3, 2021 and September 27, 2020.

Business development activities impacted financial results in the periods presented. See Note 1A in our 2020 Form 10-K, and Note 2. On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see Note 2B in our 2020 Form 10-K. On December 21, 2020, which fell in Pfizer s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November 13, 2020, and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations. Prior-period information has been restated to reflect our current organization structure.

B. New Accounting Standard Adopted in 2021

On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.

For information on new accounting standards adopted in 2020, see Note 1B in our 2020 Form 10-K.

C. Change in Accounting Principle

In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting). Under the prior policy, we deferred recognition of these gains and losses in Accumulated other comprehensive loss. The accumulated actuarial gains/losses outside of a corridor were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to Retained earnings of $6.3 billion, with a corresponding offset to Accumulated other comprehensive loss. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions net.

We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:

Three Months Ended

October 3, 2021

September 27, 2020

(MILLIONS, EXCEPT PER COMMON SHARE DATA)Previous

Accounting

PrincipleImpact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Statements of Income:

Other (income)/deductions net$(641)$(1,055)$(1,696)$889 $989 $1,878

Income from continuing operations before provision/(benefit) for taxes on income6,782 1,055 7,836 1,559 (989)570

Provision/(benefit) for taxes on income(561)230 (331)(104)(243)(347)

Income/(loss) from discontinued operations net of tax(9) (9)539 21 560

Net income before allocation to noncontrolling interests7,334 825 8,159 2,202 (724)1,477

Net income attributable to Pfizer Inc. common shareholders7,322 825 8,146 2,194 (724)1,469

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$1.30 $0.15 $1.45 $0.30 $(0.13)$0.16

Income/(loss) from discontinued operations net of tax 0.10 0.10

Net income attributable to Pfizer Inc. common shareholders1.30 0.15 1.45 0.39 (0.13)0.26

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$1.27 $0.15 $1.42 $0.29 $(0.13)$0.16

Income/(loss) from discontinued operations net of tax 0.10 0.10

Net income attributable to Pfizer Inc. common shareholders1.27 0.15 1.42 0.39 (0.13)0.26

Condensed Consolidated Statements of Comprehensive Income:

Foreign currency translation adjustments, net$(961)$95 $(866)$1,609 $(206)$1,403

Benefit plans: actuarial gains/(losses), net836 (836) (1,211)1,211

Reclassification adjustments related to amortization74 (74) 67 (67)

Reclassification adjustments related to settlements, net139 (139) 174 (174)

Other95 (95) (206)206

Tax provision/(benefit) on other comprehensive income/(loss)(89)23 (65)(262)243 (19)

Nine Months Ended

October 3, 2021

September 27, 2020

(MILLIONS, EXCEPT PER COMMON SHARE DATA)Previous

Accounting

PrincipleImpact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Statements of Income:

Other (income)/deductions net$(2,414)$(1,283)$(3,697)$232 $881 $1,114

Income from continuing operations before provision/(benefit) for taxes on income18,845 1,283 20,128 7,320 (881)6,438

Provision/(benefit) for taxes on income1,237 281 1,518 647 (213)434

Income/(loss) from discontinued operations net of tax24 24 2,374 (40)2,334

Net income before allocation to noncontrolling interests17,631 1,002 18,633 9,046 (709)8,338

Net income attributable to Pfizer Inc. common shareholders17,584 1,002 18,586 9,022 (709)8,313

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$3.14 $0.18 $3.32 $1.20 $(0.12)$1.08

Income/(loss) from discontinued operations net of tax 0.43 (0.01)0.42

Net income attributable to Pfizer Inc. common shareholders3.14 0.18 3.32 1.62 (0.13)1.50

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$3.08 $0.18 $3.26 $1.18 $(0.12)$1.06

Income/(loss) from discontinued operations net of tax 0.42 (0.01)0.42

Net income attributable to Pfizer Inc. common shareholders3.09 0.18 3.27 1.60 (0.13)1.48

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Nine Months Ended

October 3, 2021

September 27, 2020

(MILLIONS)Previous

Accounting

PrincipleImpact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Statements of Comprehensive Income:

Foreign currency translation adjustments, net$(354)$(11)$(366)$96 $(123)$(27)

Benefit plans: actuarial gains/(losses), net881 (881) (1,372)1,372

Reclassification adjustments related to amortization222 (222) 200 (200)

Reclassification adjustments related to settlements, net162 (162) 240 (240)

Other(11)11 (123)123

Tax provision/(benefit) on other comprehensive income/(loss)(20)(24)(44)(527)215 (311)

Condensed Consolidated Statements of Cash Flows:

Deferred taxes from continuing operations$(3,983)$281 $(3,702)$(522)$(213)$(735)

Benefit plan contributions in excess of expense/income(650)(1,283)(1,933)(1,642)881 (760)

October 3, 2021

December 31, 2020

(MILLIONS)Previous Accounting Principle

Impact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Balance Sheets:

Noncurrent deferred tax assets and other noncurrent tax assets$3,012 $(257)$2,755 $2,383 $ $2,383

Other noncurrent assets6,687 18 6,705 4,569 4,569

Pension benefit obligations3,677 3,676 4,766 4,766

Retained earnings101,250 1,002 102,252 96,770 (6,378)90,392

Accumulated other comprehensive loss(4,408)(1,241)(5,649)(11,688)6,378 (5,310)

D. Revenues and Trade Accounts Receivable

Customers Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)October 3,

2021December 31, 2020

Reserve against Trade accounts receivable, less allowance for doubtful accounts

$996 $861

Other current liabilities:

Accrued rebates3,470 3,017

Other accruals470 436

Other noncurrent liabilities

503 399

Total accrued rebates and other sales-related accruals$5,439 $4,712

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk,

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.

During the three and nine months ended October 3, 2021 and September 27, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2020 Form 10-K.

Note 2. Discontinued Operations, Equity-Method Investment and Collaborative Arrangement

A. Discontinued Operations

Upjohn Separation and Combination with Mylan

On November 16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See Note 1A.

In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the three and nine months ended October 3, 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $197 million as of October 3, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in Net cash provided by operating activities from continuing operations, except for a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in Other financing activities, net, and was recorded as a payable to Viatris in Other current liabilities as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer s consolidated financial statements.

The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as Income/(loss) from discontinued operations net of tax.

Components of Income/(loss) from discontinued operations net of tax:

Three Months Ended(a)

Nine Months Ended(a)

(MILLIONS)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Revenues$ $1,854 $27 $5,737

Costs and expenses:

Cost of sales4 526 18 1,425

Selling, informational and administrative expenses2 359 (1)1,061

Research and development expenses 60 1 165

Amortization of intangible assets 37 109

Restructuring charges and certain acquisition-related costs 1 18

Other (income)/deductions net5 233 6 304

Pre-tax income/(loss) from discontinued operations(10)639 3 2,654

Provision/(benefit) for taxes on income(2)79 (21)320

Income/(loss) from discontinued operations net of tax$(9)$560 $24 $2,334

(a)In the third quarter of 2021, Income/(loss) from discontinued operations net of tax reflects post-closing adjustments directly related to our discontinued operations, including adjustments for legal and tax related matters. In the first nine months of 2021, Income/(loss) from discontinued operations net of tax includes the operations of the Mylan-Japan collaboration, which terminated during Pfizer s international first quarter of 2021, and post-closing adjustments directly related to our discontinued operations, including adjustments for tax, benefits and legal related matters. In the three and nine months ended September 27, 2020, Income/(loss) from discontinued operations net of tax relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See Note 1C. In the three and nine months ended September 27, 2020, Income/(loss) from discontinued operations net of tax includes interest expense of $76 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and charges of $144 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

B. Equity-Method Investment

Formation of Consumer Healthcare JV

On July 31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%.

We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $16.1 billion as of October 3, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in Equity-method investments as of October 3, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $549 million in pre-tax foreign currency translation adjustments (see Note 6), as well as dividends totaling approximately $295 million, partially offset by our share of the JV s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions net. Our total share of the JV s earnings generated in the second quarter of 2021, which we recorded in our operating results in the third quarter of 2021, was $106 million. Our total share of the JV s earnings generated in the fourth quarter of 2020 and first six months of 2021, which we recorded in our operating results in the first nine months of 2021, was $324 million. Our total share of the JV s earnings generated in the second quarter of 2020, which we recorded in our operating results in the third quarter of 2020, was $166 million. Our total share of the JV s earnings generated in the fourth quarter of 2019 and first six months of 2020, which we recorded in our operating results in the first nine months of 2020, was $306 million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in Other (income)/deductions net and was not material to our results of operations in the periods presented. See Note 4.

Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three and nine months ending June 30, 2021, the most recent period available, and for the three and nine months ending June 30, 2020, is as follows:

Three Months EndedNine Months Ended

(MILLIONS)June 30,

2021June 30,

2020June 30,

2021June 30,

2020

Net sales$3,152 $2,927 $9,428 $9,618

Cost of sales(1,180)(1,061)(3,536)(4,266)

Gross profit$1,972 $1,866 $5,892 $5,352

Income from continuing operations348 524 1,064 995

Net income348 524 1,064 995

Income attributable to shareholders330 518 1,012 959

C. Collaboration Arrangement

Collaboration with Arvinas

On July 22, 2021, we announced a global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. Under the terms of the collaboration agreement, we made an upfront payment to Arvinas of $650 million in July 2021, which was recorded to Research and development expenses. On September 13, 2021, we made a $350 million equity investment in Arvinas, receiving approximately 3.5 million newly issued shares of Arvinas common stock, priced at a 30% premium to the 30-day volume weighted average price on July 20, 2021, representing an equity ownership stake by Pfizer of approximately 7% as of September 13, 2021. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones. The companies will equally share worldwide development costs, commercialization expenses and profits.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Transforming to a More Focused Company Program

With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:

We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $1.6 billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.

In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $1.1 billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.

We are also optimizing our manufacturing network and incurring certain legacy cost-reduction initiatives related to our manufacturing business. We expect to incur costs of $500 million, with approximately 20% of the costs to be non-cash. The costs for this effort include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.

The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.

From the start of this program in the fourth quarter of 2019 through October 3, 2021, we incurred costs of $2.0 billion.

B. Key Activities

The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:

Three Months EndedNine Months Ended

(MILLIONS)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Restructuring charges/(credits):

Employee terminations

$630 $(15)$649 $340

Asset impairments

10 20 9 43

Exit costs/(credits)3 (11) (10)

Restructuring charges/(credits)(a)

643 (5)657 374

Transaction costs(b)

14

Integration costs and other(c)

3 7 11 29

Restructuring charges and certain acquisition-related costs

646 2 668 417

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net(d)

(63) (51)2

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(e):

Cost of sales

23 4 64 14

Selling, informational and administrative expenses

8 23

Research and development expenses

(3)

Total additional depreciation asset restructuring

31 4 87 10

Implementation costs recorded in our condensed consolidated statements of income as follows(f):

Cost of sales

8 9 29 27

Selling, informational and administrative expenses

142 36 287 114

Research and development expenses

1 1 2

Total implementation costs

151 47 316 142

Total costs associated with acquisitions and cost-reduction/productivity initiatives

$764 $52 $1,020 $571

(a)Primarily represents cost reduction initiatives.

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(d)Amounts for the three and nine months ended September 27, 2020 include the impact of a change in accounting principle. See Note 1C.

(e)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(f)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2020(a)

$782 $ $15 $798

Provision649 9 657

Utilization and other(b)

(306)(9)(5)(319)

Balance, October 3, 2021(c)

$1,125 $ $10 $1,135

(a)Included in Other current liabilities ($628 million) and Other noncurrent liabilities ($169 million).

(b)Includes adjustments for foreign currency translation.

(c)Included in Other current liabilities ($860 million) and Other noncurrent liabilities ($275 million).

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months EndedNine Months Ended

(MILLIONS)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Interest income$(10)$(15)$(21)$(68)

Interest expense325 345 975 1,102

Net interest expense

315 330 954 1,034

Royalty-related income(261)(214)(649)(524)

Net (gains)/losses on asset disposals(1)(2)(99)

Net (gains)/losses recognized during the period on equity securities(a)

(400)70 (1,601)(408)

Income from collaborations, out-licensing arrangements and sales of compound/product rights(b)

(65)(30)(317)(245)

Net periodic benefit costs/(credits) other than service costs(c)

(1,132)1,043 (1,635)749

Certain legal matters, net(d)

38 (17)458 5

Certain asset impairments(e)

900 900

Consumer Healthcare JV equity method (income)/loss(f)

(105)(103)(307)(196)

Other, net(84)(99)(501)(202)

Other (income)/deductions net$(1,696)$1,878 $(3,697)$1,114

(a)The gains in the third quarter and first nine months of 2021 include, among other things, unrealized gains of $420 million and $1.5 billion, respectively, related to investments in BioNTech and Cerevel Therapeutics, LLC. The losses in the third quarter of 2020 included, among other things, unrealized losses of $131 million related to our investment in Allogene. The gains in the first nine months of 2020 included, among other things, unrealized gains of $397 million related to our investments in Allogene and BioNTech.

(b)The first nine months of 2021 includes, among other things, $188 million of net collaboration income from BioNTech in the first quarter of 2021 related to the COVID-19 vaccine. The first nine months of 2020 mainly included, among other things, (i) an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc., (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU and (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC.

(c)Amounts include the impact of a change in accounting principle. See Notes 1C and 10.

(d)The first nine months of 2021 primarily includes an amount to resolve a Multi-District Litigation relating to EpiPen pending against the Company in the U.S. District Court for the District of Kansas for $345 million, which remains subject to court approval. See Note 12A5.

(e)The third quarter and first nine months of 2020 included intangible asset impairment charges of $900 million related to IPR&D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts.

(f)See Note 2B.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was (4.2)% for the third quarter of 2021, compared to (60.9)% for the third quarter of 2020, and was 7.5% for the first nine months of 2021, compared to 6.7% for the first nine months of 2020.

The negative effective tax rate for the third quarter of 2021 was primarily a result of certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK based on estimates and assumptions

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

that we believe to be reasonable. The negative effective tax rate for the third quarter of 2020 was primarily a result of benefits associated with certain intangible asset impairments (see Note 4(e)). The increase in the effective tax rate for the first nine months of 2021, compared to the first nine months of 2020, was due to the change in the jurisdictional mix of earnings primarily related to Comirnaty and the non-recurrence of benefits associated with certain intangible asset impairments, partially offset by certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date. The fourth annual installment is due April 15, 2022 and is reported in current Income taxes payable as of October 3, 2021. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2011.

For additional information, see Note 5D in our 2020 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months EndedNine Months Ended

(MILLIONS)October 3,

2021September 27,

2020October 3,

2021September 27,

2020

Foreign currency translation adjustments, net(a)

$(32)$10 $(30)$(167)

Unrealized holding gains/(losses) on derivative financial instruments, net21 (43)28 (126)

Reclassification adjustments for (gains)/losses included in net income13 7 48 (13)

34 (37)76 (139)

Unrealized holding gains/(losses) on available-for-sale securities, net(33)30 (16)29

Reclassification adjustments for (gains)/losses included in net income1 (11)(22)(3)

(32)19 (37)26

Reclassification adjustments related to amortization of prior service costs and other, net

(22)(11)(39)(32)

Reclassification adjustments related to curtailments of prior service costs and other, net(14) (14)

Other (1)(1)1

(36)(11)(54)(31)

Tax provision/(benefit) on other comprehensive income/(loss)$(65)$(19)$(44)$(311)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

18

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2020(a)

$(5,450)$(428)$116 $452 $(5,310)

Other comprehensive income/(loss)(b)

(336)388 (262)(127)(338)

Balance, October 3, 2021$(5,787)$(40)$(146)$325 $(5,649)

(a)Amounts include the impact of a change in accounting principle. See Note 1C.

(b)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses related to our equity method investment in the Consumer Healthcare JV (see Note 2B) and net gains related to the impact of our net investment hedging program.

19

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

October 3, 2021December 31, 2020

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Classified as equity securities with readily determinable fair values:

Money market funds$2,367 $ $2,367 $567 $ $567

Classified as available-for-sale debt securities:

Government and agency non-U.S.

16,826 16,826 7,719 7,719

Government and agency U.S.

4,881 4,881 982 982

Corporate and other

1,181 1,181 1,008 1,008

22,887 22,887 9,709 9,709